Clinical Trial in Nephrology at Hard End Point?

Journal of the American Society of Nephrology

Volumn 15, Issue 2, 2004, Pages 506-508

  De Zeeuw, Dick ^a   De Graeff, Pieter A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEW DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EDITORIAL; HUMAN; KIDNEY FUNCTION; MEDICAL LITERATURE; MEDICAL SPECIALIST; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT;

EID: 0942287095     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000113164.35698.49     Document Type: Editorial

References (13)

1. Strippoli GFM, Craig JC, Schena FP: The number, quality and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15: 411-419, 2004
2. Hostetter TH: The next treatments of chronic kidney disease: if we find them, can we test them? J Am Soc Nephrol 13: 3024-3026, 2002
3. Brenner BM, Cooper MA, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
5. Rao M, Pereira BJ: Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Kidney Int Suppl 87: S12-S19, 2003
6. Ridker PM, JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108: 2292-2297, 2003
7. Who's afraid of the European clinical trials Directive? Lancet 361: 2167, 2003
8. Rahman M, Fukui T: A decline in the U.S. share of research articles. N Engl J Med 347: 1211, 2002
9. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003
10. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767-771, 2003
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
12. GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863, 1997
13. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884, 1994